NCT01625403

Recombinant BNP on Heart and Renal Function in Acute Heart Failure

Effect of Recombinant BNP on Heart and Renal Function in Acute Decompensated Heart Failure Patients With Acute Renal Injury

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Shanghai Chest Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of recombinant human B-type natriuretic peptide (rhBNP) on heart and renal function in patients with acute decompensated heart failure (ADHF) and acute renal injury (AKI).

Detailed description

Patients with acute decompensated heart failure (ADHF) and acute renal injury (AKI) will be randomized to receive standard of care with or without additional rhBNP. Clinical heart function, LVEF, SCr, GFR and other laboratory parameters will be evaluated.

Conditions

• Acute Heart Failure
• Acute Renal Failure

Interventions

Type	Name	Description
DRUG	rhBNP	intravenous administration of rhBNP 0.01 µg/kg/min
DRUG	standard of care	standard of care for heart failure

Timeline

• Start date: 2012-07-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2012-06-21
• Last updated: 2012-08-07

Locations

1 site across 1 country: China